Dr Sue Chua

Consultant Radiologist and Nuclear Medicine Physician MBBS BSc MRCPCH FRCR

Specialism: Cancer genetics, Children and young people, Drug development, Gastrointestinal, Neuro-oncology, Nuclear medicine, Urology

Available at: Chelsea, Sutton

Special interests:

  • oncologic 18F FDG PET/CT
  • 18F Choline PET/CT for prostate and brain cancers
  • general nuclear medicine and SPECT/CT
  • functional imaging


Dr Sue Chua has both a private and an NHS practice at The Royal Marsden. She is a Multimodality Imaging Consultant with dual accreditation in radiology and nuclear medicine. She graduated in Sydney, Australia, in 1997 and undertook radiology training in Nottingham (2001–05) and nuclear medicine and PET/CT training (2005-07) in Nottingham, the Institute of Nuclear Medicine at UCLH, and the Oklahoma Heart Hospital, USA.

Dr Chua was appointed to The Royal Marsden in 2008 with a remit to support and develop PET/CT research activity. Her research interests are principally in multimodality functional imaging, in particular PET/CT and functional CT and MRI imaging, which have an increasingly important role in detecting changes in tumours at the cellular and molecular level, in order to offer improved outcome prediction and treatment efficacy assessment in cancer management. Her clinical and research areas of interest include urology, paediatric oncology, lymphomas, upper and lower GI, lung and neuro-oncology.

She is actively involved in many prospective trials (listed below), in both single and multi-centre settings, locally, nationally and internationally. She is a member of the EORTC PET imaging and lung groups and also the NCRI Brain (Clinical Trials Unit) CSG Imaging Subgroup. Locally, at The Royal Marsden and The Institute of Cancer Research, she is PET/CT trial advisor for the Phase 1 Drug Development Unit.

She established the 18F Choline PET/CT service at The Royal Marsden, the first centre in the UK to offer 18F Choline PET for brain tumour evaluation, and the second centre to use this tracer in the setting of prostate cancer. She has trained staff from several PET centres in the country in 18F Choline PET to enable them to establish their own service.

Clinical PET trials led by Sue Chua

  • Pre-treatment Staging and Post-treatment Assessment in Malignant Lymphoma by Whole Body Diffusion-weighted MR Imaging (WB-DWI) and ADC-mapping in comparison to 18F-FDG PET/CT. (Chief investigator)
  • A phase II proof-of-concept study to compare the novel technique [124I]mIBG PET/CT to [123I]mIBG scintigraphy in patients with metastatic neuroblastoma (CRUKD/12/002). (Chief investigator)
  • A multicentre trial to evaluate the role of 18F-FDG PET/CT as a surrogate biomarker for prediction of treatment response and prognosis, following the first course of neoadjuvant chemotherapy in resectable oesophageal adenocarcinoma. (Chief investigator)
  • Utility of 18-F Choline PET/CT in the management of testicular germ cell tumours. (Chief investigator)
  • F Choline PET substudy in DELINEATE (Dose Escalation to Intra-prostatic Tumour Nodules in Localised Prostate Cancer)- - 18F-FDG PET/CT imaging lead
  • Tumour angiogenesis, hypoxia and metabolism in oesophageal cancer with multiPET tracers (18F FDG, 18F MISO, 82Rb): PET/CT and hybrid PET/MRI Radiology-Pathology and Prognostic Correlation. (Collaboration with INM UCL) (Principle investigator)
  • Cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) versus gemcitabine, cisplatin and methyl prednisolone (GEM-P) in the first line treatment of T-cell Lymphoma, a multicentre randomised phase II study with pre and post treatment PET-CT response assessment- 18F-FDG PET/CT imaging lead
  • Proof-of-concept biomarker study of AZD4547 in patients with FGFR1 / FGFR2 amplified tumours (a multicentre phase I trial with 18F FDG PET/CT response assessment)- 18F-FDG PET/CT imaging lead
  • A Phase I trial of RO5126766 (a dual RAF/MEK inhibitor) exploring intermittent, oral dosing regimens in patients with solid tumours or multiple myeloma”. Treatment response assessment with 18F Choline PET/CT and Diffusion-weighted MRI- 18F-Choline PET/CT imaging lead
  • A Cancer Research UK Phase I first in man study of the novel AGC kinase inhibitor AT13148 given orally in patients with advanced solid tumours- 18F-FDG PET/CT imaging lead
  • Timing of Rectal Surgery Following a Continued Incremental Response to Pre-operative Chemoradiotherapy – “Deferral of Surgery” – 18F-FDG PET/CT imaging lead
  • Is greater downstaging and tumour regression observed when surgery is delayed to 12 weeks after completion of CRT vs 6 weeks – 18F-FDG PET/CT imaging lead

Clinical units